\neSource capability will enable paperless clinical trials<\/em><\/p>\n
BARCELONA \u2014 2020 Veeva R&D Summit, Europe \u2014 19 May, 2020 \u2014 <\/strong> Veeva Systems<\/a> (NYSE:VEEV) today announced MyVeeva for Patients, a new application for clinical research sites. With capabilities for virtual visits, patient adherence, ePRO, eConsent, eSource and an easy to use patient portal, MyVeeva for Patients will make it easier for clinical research sites to deliver a patient-centric and paperless clinical trial experience for patients and sponsors. MyVeeva for Patients is free for clinical research sites and integrates seamlessly with Veeva SiteVault<\/a>.<\/p>\n \u201cThere is a pressing need for clinical solutions that reduce the burden on patients participating in trials and make study execution easier for sites,\u201d said Jessica Collins, program director for investigator-initiated clinical trials at Vanderbilt University Medical Center. \u201cHaving the ability to conduct parts of a study remotely is key to a better patient experience and speeding study conduct. It\u2019s a crucial shift for the industry and I appreciate the innovation Veeva is bringing to this important area.\u201d<\/p>\n MyVeeva for Patients enables patients, doctors, and clinical research coordinators to collaborate remotely with advanced audio and video capabilities, reducing the need for in-person visits. Clinical researchers can collect and record patient data electronically; make it more convenient for patients to report on treatment outcomes; easily share information electronically and get patient consent; and help patients take medications and adhere to their treatment regimens.<\/p>\n \u201cCOVID-19 created even greater urgency for clinical trials to become more virtual and deliver a safe, convenient patient experience,\u201d said Henry Levy, general manager of Vault CDMS<\/a>, site, and patient solutions at Veeva. \u201cEnabling home-based trial visits with MyVeeva for Patients can advance the move to more patient-centric and paperless trials. We are excited to partner with the industry to help improve the clinical trial process for sponsors, sites, and patients.\u201d<\/p>\n Sites will have the flexibility to use MyVeeva for Patients with Veeva SiteVault and Veeva Vault Clinical<\/a> applications, as well as third-party clinical applications. MyVeeva for Clinical Trials is planned for availability in December 2020.<\/p>\n MyVeeva for Patients is part of the Veeva Clinical Network, a set of solutions that brings together sponsors, sites, and patients to accelerate clinical research. In addition to MyVeeva, Veeva today announced Veeva Site Connect<\/a>, a new application that connects sponsors and clinical research sites during trials. Together with Veeva Vault Clinical Suite<\/a>, Veeva is the first and only company providing solutions that help sponsors, sites, and patients share and view information during a clinical trial. For more information on how Veeva will enable patient-centric trials, contact info@veeva.com<\/a>.<\/p>\n Additional Information<\/strong> About Veeva Systems<\/strong> Forward-looking Statements<\/strong> ###<\/p>\n![\"MyVeeva](\"https:\/\/www.veeva.com\/wp-content\/uploads\/2020\/10\/MyVeeva-for-Patients-1440x811-1.png\")
Doctors can conduct virtual visits and make it easier for patients
to participate in clinical trials.<\/span>\n<\/div>\n
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veevasystems on Twitter: twitter.com\/veeva_eu<\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n
\nVeeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-K for the period ended January 31, 2020. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n